Cell Biosciences Launches Two New Platforms
Santa Clara, CA, April 15, 2010 — Cell Biosciences, Inc., a provider of innovative protein analysis tools to life science researchers, today announced the launch of two new platforms for ultrasensitive protein characterization. Both platforms will be unveiled at the American Association for Cancer Research (AACR) 101st Annual Meeting, April 17-21, 2010 in Washington, DC (booth 719).
The new NanoPro™ 100 system builds upon the success of the NanoPro CB1000 platform, which was introduced in 2009. The NanoPro CB1000 has been adopted by many of the world's foremost drug development and translational medicine researchers, with nearly 30 systems placed in the past nine months. The NanoPro 100 offers the same analytical power as the high-throughput NanoPro CB1000 system, but in a compact, benchtop system designed for lower-throughput laboratories and individual investigators. The NanoPro 100 is the first system that gives researchers access to revolutionary NanoPro technology for under $100,000.
NanoPro assay technology enables detailed characterization of proteins in extremely small and precious samples, such as tumor micro-biopsies and isolated stem cell populations. NanoPro assays are used to uncover fundamental mechanisms controlling cell proliferation and cell death, to accelerate the development of new therapeutics, and to help identify new prognostic and diagnostic disease biomarkers. Current NanoPro customers include leading institutions and companies in the fields of cancer research, stem cell biology, diabetes, and drug development.
Also being launched at AACR 2010 is the FluorChem® E Digital Darkroom, which sets a new standard for high-performance chemiluminescent Western blot and gel imaging. The FluorChem E system features unparalleled sensitivity and resolution for Western blot analysis, and represents the first member of Cell Biosciences' next-generation imaging product line. The system's innovative design incorporates state-of-the-art CCD technology and intuitive touch screen control for effortless analysis of chemiluminescent, colorimetric, and UV-fluorescent samples. FluorChem E's novel imaging software enables convenient file access from any internet-enabled device, such as Apple's iPhone® or iPad™.
“Cell Biosciences is committed to expanding its product leadership position in protein analysis,” commented Walter Ausserer, Ph.D., Vice President of Marketing at Cell Biosciences. “We believe that customers will be delighted by the innovative features and exceptional performance of the NanoPro 100 and FluorChem E systems, and that these new platforms will be key drivers for our continued growth.”
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on defining the future of protein analysis. The Company develops instrumentation systems, sample preparation systems, software and assay products that drive discoveries in fields ranging from fundamental protein research to biomarker discovery and personalized medicine. With an installed base of over 10,000 systems, its customers include leading research institutions, pharmaceutical and biotechnology companies worldwide. Cell Biosciences is headquartered in Santa Clara, California. For more information, visit www.cellbiosciences.com.
CONTACT: Walter Ausserer, Ph.D., Vice President of Marketing, Cell Biosciences, Inc., +1-408-510-5503, wausserer@cellbiosciences.com